AtriCure, Inc. · NASDAQ (us_market)
Healthcare · Medical Instruments & Supplies · United States
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-08-26$37.87 RISE2025-11-06$31.50 PEAK2026-01-08$42.41 135d | -16.8% 72d | Missed | Missed | — | — | +34.6% 63d | Missed |
DROP2025-03-24$35.09 RISE2025-07-21$29.24 PEAK2025-08-26$37.87 155d | -16.7% 119d | Missed | Missed | — | — | +29.5% 36d | Missed |
DROP2025-01-29$42.40 RISE2025-05-05$29.07 PEAK2025-07-30$35.13 182d | -31.4% 96d | Missed | Missed | — | — | +20.8% 86d | Missed |
DROP2024-11-11$38.20 RISE2024-12-19$30.05 PEAK2025-01-29$42.40 79d | -21.3% 38d | Missed | Missed | — | — | +41.1% 41d | Missed |
DROP2024-03-28$30.42 RISE2024-08-07$20.34 PEAK2024-10-30$34.83 216d | -33.1% 132d | Missed | Missed | — | — | +71.2% 84d | Missed |
DROP2024-03-05$37.78 RISE2024-06-17$19.86 PEAK2024-09-12$27.71 191d | -47.4% 104d | Missed | Missed | — | — | +39.5% 87d | Missed |
DROP2024-03-05$37.78 RISE2024-05-08$20.69 PEAK2024-07-16$25.30 133d | -45.2% 64d | Missed | Missed | — | — | +22.3% 69d | Missed |
DROP2023-11-15$42.53 RISE2024-02-13$31.71 PEAK2024-03-05$37.78 111d | -25.4% 90d | Missed | Missed | — | — | +19.1% 21d | Missed |
DROP2023-07-26$57.73 RISE2023-10-27$33.34 PEAK2023-11-15$42.53 112d | -42.2% 93d | Missed | Missed | — | — | +27.6% 19d | Missed |
DROP2022-11-15$47.45 RISE2023-03-10$35.87 PEAK2023-05-22$49.32 188d | -24.4% 115d | Missed | Missed | — | — | +37.5% 73d | Missed |
DROP2022-08-15$52.62 RISE2022-10-14$33.48 PEAK2022-11-15$47.45 92d | -36.4% 60d | Missed | Missed | — | — | +41.7% 32d | Missed |
DROP2022-03-02$71.15 RISE2022-06-16$35.10 PEAK2022-08-15$52.62 166d | -50.7% 106d | Missed | Missed | — | — | +49.9% 60d | Missed |
DROP2021-11-05$87.14 RISE2022-03-14$57.43 PEAK2022-03-18$66.36 133d | -34.1% 129d | Missed | Missed | — | — | +15.5% 4d | Missed |
DROP2021-11-05$87.14 RISE2022-01-27$59.39 PEAK2022-03-02$71.15 117d | -31.8% 83d | Missed | Missed | — | — | +19.8% 34d | Missed |
DROP2021-11-05$87.14 RISE2021-11-30$63.40 PEAK2021-12-23$73.36 48d | -27.2% 25d | Missed | Missed | — | — | +15.7% 23d | Missed |
1–15 / 18 1 / 2 | |||||||
The medical device maker flags a drop in stand-alone procedures for its Watchman heart implant, hitting its near-term growth forecast.
AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding opportunities in pain management and appendage management. Speaking at a Bank of America fireside
AtriCure, Inc. (ATRC) Bank of America Global Healthcare Conference 2026 May 12, 2026 1:00 PM EDTCompany ParticipantsAngela Wirick - Chief Financial...
Presenter SpeechUnknown Analyst [Audio Gap] CEO Mike Carrel and CFO, Angie Wirick; we're going to do a 30-minute fireside chat, but thanks, everyone, for joining us. .QuestionUnknown Analyst I
Recent performance snapshot AtriCure (ATRC) has drawn investor attention after a difficult stretch for the stock, with a return of around a 29% decline year to date and about a 25% decline over the past 3 months. See our latest analysis for AtriCure. With the share price at $27.80, AtriCure’s 30 day share price return of about 4% decline and 1 year total shareholder return of roughly 11% decline point to momentum that has been fading rather than building recently. If you are reassessing risk...
2026-05-08. The following slide deck was published by AtriCure, Inc.
Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $53 to $55.
AtriCure is off to a strong start in 2026 with worldwide revenue of $140 million in the first quarter, reflecting 14% growth year-over-year. Fueling this acceleration is our U.S. business, which drove approximately 15% in the quarter from expanding adoption of AtriClip FLEX-Mini and PRO-Mini devices, cryoSPHERE MAX probe and continued strength from our EnCompass clamp. Beyond our financial results, we have made exceptional progress in our BoxX-NoAF clinical trial.
AtriCure May 5, 2026 Corporate Speakers Marissa Bych; Gilmartin Group; Managing Director ...
Moby summary of AtriCure, Inc.'s Q1 2026 earnings call
AtriCure, Inc. (ATRC) Q1 2026 Earnings Call May 5, 2026 4:30 PM EDTCompany ParticipantsMichael H.
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Presentation Operator MessageOperator Good afternoon, and welcome to AtriCure's First Quarter 2026 Earnings Conference Call. This call is being recorded for replay purposes. [Operator Instructions]
AtriCure (NASDAQ:ATRC) reported first-quarter 2026 results that management described as an accelerated growth start to the year, highlighted by double-digit revenue gains and improved profitability alongside faster-than-expected enrollment in a key clinical trial. Revenue rose 14% as U.S. adoption
AtriCure (ATRC) delivered earnings and revenue surprises of +100.00% and +1.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
AtriCure Q1 results beat estimates with first-ever GAAP net income breakeven, revenue of $141.2M up 14.3% YoY, and strong growth in pain management sales.
2026 Financial GuidanceFull year 2026 revenue is projected to be approximately $600 million to $610 million, and management also projects full year 2026 Adjusted EBITDA of approximately $80 million to $82 million.
AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.06) by 100 percent. This is a 100 percent increase over losses of $(0.14) per share from the same
First Quarter 2026 worldwide revenue of $141.2 million, an increase of 14.3% year over yearFirst Quarter 2026 profitability improved, with net income of $0.1 million and adjusted EBITDA of $17.1...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ATRC | -4.65% | -10.54% | -30.06% | -19.96% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -7.62% | -4.82% | -26.61% | -32.65% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| Wellington | fundamental | 3.38M | $96.50M | 0.02% | Trimmed-13.7% | 2026-03-31 |
| StateStreet | passive | 1.30M | $37.15M | 0.00% | Added+4.8% | 2026-03-31 |
| TwoSigma | quant | 751.0K | $21.43M | 0.02% | Added+97.4% | 2026-03-31 |
| FidelityFMR | fundamental | 336.8K | $9.61M | 0.00% | Added+17.9% | 2026-03-31 |
| RenTech | quant | 308.7K | $8.81M | 0.01% | Trimmed-4.1% | 2026-03-31 |
| DEShaw | quant | 56.6K | $1.61M | 0.00% | New | 2026-03-31 |
| Bridgewater | macro | 33.5K | $956.24K | 0.00% | New | 2026-03-31 |
| TRowePrice | fundamental | 60.3K | $1.72K | 0.00% | Added+19.2% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-28upcoming | 0.02 | — | — |
| 2026-05-05 | -0.06 | — | +100.00% |
| 2026-02-17 | -0.04 | 0.06 | +249.89% |
| 2025-10-29 | -0.12 | -0.01 | +91.49% |
| 2025-07-29 | -0.16 | -0.02 | +87.71% |
| 2025-04-29 | -0.22 | -0.14 | +37.32% |
| 2025-02-12 | -0.15 | -0.08 | +46.22% |
| 2024-10-29 | -0.20 | -0.17 | +13.44% |
| 2024-07-30 | -0.17 | -0.17 | +0.23% |
| 2024-05-01 | -0.23 | -0.25 | -8.30% |
| 2024-02-15 | -0.23 | -0.21 | +7.97% |
| 2023-11-01 | -0.31 | -0.20 | +35.72% |
| 2023-07-25 | -0.31 | -0.12 | +61.56% |
| 2023-05-02 | -0.35 | -0.23 | +34.25% |
| 2023-02-21 | -0.18 | -0.09 | +49.54% |
| 2022-11-01 | -0.25 | -0.27 | -5.88% |